274 related articles for article (PubMed ID: 24791854)
21. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
Tefferi A; Lasho TL; Finke CM; Knudson RA; Ketterling R; Hanson CH; Maffioli M; Caramazza D; Passamonti F; Pardanani A
Leukemia; 2014 Jul; 28(7):1472-7. PubMed ID: 24402162
[TBL] [Abstract][Full Text] [Related]
22. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
23. Thrombotic risk correlates with mutational status in true essential thrombocythemia.
Bertozzi I; Peroni E; Coltro G; Bogoni G; Cosi E; Santarossa C; Fabris F; Randi ML
Eur J Clin Invest; 2016 Aug; 46(8):683-9. PubMed ID: 27271054
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].
Ben Said M; Gandrille S; Fischer AM; Darnige L
Pathol Biol (Paris); 2015 Jun; 63(3):117-21. PubMed ID: 25840625
[TBL] [Abstract][Full Text] [Related]
25. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.
Usseglio F; Beaufils N; Calleja A; Raynaud S; Gabert J
J Mol Diagn; 2017 Jan; 19(1):92-98. PubMed ID: 27855276
[TBL] [Abstract][Full Text] [Related]
26. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
[TBL] [Abstract][Full Text] [Related]
27. Mutational profiling in suspected triple-negative essential thrombocythaemia using targeted next-generation sequencing in a real-world cohort.
Michail O; McCallion P; McGimpsey J; Hindley A; Greenfield G; McAllister R; Feerick J; Arnold C; Cross N; Cuthbert R; McMullin MF; Catherwood MA
J Clin Pathol; 2021 Dec; 74(12):808-811. PubMed ID: 33144355
[TBL] [Abstract][Full Text] [Related]
28. MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients.
ElNahass YH; Mahmoud HK; Mattar MM; Fahmy OA; Samra MA; Abdelfattah RM; ElRefaey FA; Fahmy HM; Fathy GM; Abdulgawad A; AbdelKader M; Elleithy HN; Gamil M; Talaat M; Nader HA; ElMetnawy WH
Leuk Lymphoma; 2018 Apr; 59(4):844-854. PubMed ID: 28828906
[TBL] [Abstract][Full Text] [Related]
29. Anagrelide and Mutational Status in Essential Thrombocythemia.
Iurlo A; Cattaneo D; Orofino N; Bucelli C; Fabris S; Cortelezzi A
BioDrugs; 2016 Jun; 30(3):219-23. PubMed ID: 27041108
[TBL] [Abstract][Full Text] [Related]
30. JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia.
Pich A; Riera L; Francia di Celle P; Beggiato E; Benevolo G; Godio L
Acta Haematol; 2018; 140(4):234-239. PubMed ID: 30404086
[TBL] [Abstract][Full Text] [Related]
31. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
32. Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2
Saki N; Shirzad R; Rahim F; Saki Malehi A
Clin Transl Oncol; 2017 Jul; 19(7):874-883. PubMed ID: 28205126
[TBL] [Abstract][Full Text] [Related]
33. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.
Pérez Encinas MM; Sobas M; Gómez-Casares MT; Abuin Blanco A; Noya Pereira MS; Raya JM; Andrade-Campos MM; Álvarez Larrán A; Lewandowski K; Łukasz S; Hernández Boluda JC; Ferrer-Marín F; Fox ML; Gołos A; Gasior Kabat M; Magro Mazo E; Czyż A; Martín Martín A; Bellosillo Paricio B; Quinteiro García C; González Martín JM; Stuckey R
Eur J Haematol; 2021 Mar; 106(3):371-379. PubMed ID: 33275803
[TBL] [Abstract][Full Text] [Related]
34. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
35. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
36.
Furuya C; Hashimoto Y; Morishita S; Inano T; Ochiai T; Shirane S; Edahiro Y; Araki M; Ando M; Komatsu N
Hematology; 2023 Dec; 28(1):2229131. PubMed ID: 37378567
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of Clinical Characteristics of
Li YM; Yang EP; Wang ZQ; Wang DH; Niu JC; Li YJ; Ming J; Sun MQ; Chen Z; Liu WY; Lyu Y; Hu XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):197-201. PubMed ID: 38387921
[TBL] [Abstract][Full Text] [Related]
38. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E; Pietra D; Pascutto C; Guglielmelli P; Martínez-Trillos A; Casetti I; Colomer D; Pieri L; Pratcorona M; Rotunno G; Sant'Antonio E; Bellini M; Cavalloni C; Mannarelli C; Milanesi C; Boveri E; Ferretti V; Astori C; Rosti V; Cervantes F; Barosi G; Vannucchi AM; Cazzola M;
Blood; 2014 Aug; 124(7):1062-9. PubMed ID: 24986690
[TBL] [Abstract][Full Text] [Related]
39. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
[TBL] [Abstract][Full Text] [Related]
40. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.
Tefferi A; Wassie EA; Guglielmelli P; Gangat N; Belachew AA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Pacilli A; Vannucchi AM; Passamonti F
Am J Hematol; 2014 Aug; 89(8):E121-4. PubMed ID: 24753125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]